PRX302

Protox received clearance from the United States Food and Drug Administration (FDA) in January of 2006 to commence Phase I clinical studies with PRX302 for patients with locally recurrent prostate cancer. The clinical trial began in May with the first patient treated at Scott and White Hospital in Temple, Texas. PRX302 is expected to have a therapeutic effect that will last much longer and have fewer side effects than current treatments.

Protox is also developing PRX302 for the treatment of benign prostatic hyperplasia or BPH. A Clinical Trial Application (CTA) is expected to be submitted to Health Canada and a phase I clinical trial initiated during the second half of 2006.